This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

2 Mar 2011

Novavax Announces New Licensing Deal with Asian Pharma Firm

LG Life Sciences is buying exclusive rights to manufacture, develop and commercialize influenza vaccines using Novavax's technology.

Novavax on Monday announced a deal to license its proprietary recombinant virus-like-particle vaccine technology to LG Life Sciences.


The agreement allows LG Life Sciences allows to exclusively manufacturer, develop and commercialise vaccines in South Korea, and a non-exclusive license to perform these activities in specific emerging markets.


LG Life Sciences will be responsible for the funding of clinical development and licensure of the vaccines, as well as the construction of a new manufacturing facility planned at the company's campus in Osong, South Korea.


Novavax will receive upfront and milestone payments, as

Related News